JP2018516247A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516247A5
JP2018516247A5 JP2017555557A JP2017555557A JP2018516247A5 JP 2018516247 A5 JP2018516247 A5 JP 2018516247A5 JP 2017555557 A JP2017555557 A JP 2017555557A JP 2017555557 A JP2017555557 A JP 2017555557A JP 2018516247 A5 JP2018516247 A5 JP 2018516247A5
Authority
JP
Japan
Prior art keywords
polypeptide
domain
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017555557A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018516247A (ja
JP6894846B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/027424 external-priority patent/WO2016171980A1/en
Publication of JP2018516247A publication Critical patent/JP2018516247A/ja
Publication of JP2018516247A5 publication Critical patent/JP2018516247A5/ja
Application granted granted Critical
Publication of JP6894846B2 publication Critical patent/JP6894846B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017555557A 2015-04-24 2016-04-14 Ｈｉｖ融合体を標的とするポリペプチド Expired - Fee Related JP6894846B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562152271P 2015-04-24 2015-04-24
US62/152,271 2015-04-24
US201562257474P 2015-11-19 2015-11-19
US62/257,474 2015-11-19
PCT/US2016/027424 WO2016171980A1 (en) 2015-04-24 2016-04-14 Polypeptides targeting hiv fusion

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020174288A Division JP2021035951A (ja) 2015-04-24 2020-10-16 Ｈｉｖ融合体を標的とするポリペプチド

Publications (3)

Publication Number Publication Date
JP2018516247A JP2018516247A (ja) 2018-06-21
JP2018516247A5 true JP2018516247A5 (enExample) 2019-04-25
JP6894846B2 JP6894846B2 (ja) 2021-06-30

Family

ID=55809237

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017555557A Expired - Fee Related JP6894846B2 (ja) 2015-04-24 2016-04-14 Ｈｉｖ融合体を標的とするポリペプチド
JP2020174288A Pending JP2021035951A (ja) 2015-04-24 2020-10-16 Ｈｉｖ融合体を標的とするポリペプチド
JP2023014947A Active JP7465378B2 (ja) 2015-04-24 2023-02-03 Ｈｉｖ融合体を標的とするポリペプチド

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020174288A Pending JP2021035951A (ja) 2015-04-24 2020-10-16 Ｈｉｖ融合体を標的とするポリペプチド
JP2023014947A Active JP7465378B2 (ja) 2015-04-24 2023-02-03 Ｈｉｖ融合体を標的とするポリペプチド

Country Status (25)

Country Link
US (2) US10407490B2 (enExample)
EP (2) EP3286212B1 (enExample)
JP (3) JP6894846B2 (enExample)
KR (1) KR20170138558A (enExample)
CN (1) CN107922474A (enExample)
AU (2) AU2016252008B2 (enExample)
BR (1) BR112017022790A2 (enExample)
CA (1) CA2983276A1 (enExample)
CL (1) CL2017002687A1 (enExample)
CO (1) CO2017011583A2 (enExample)
CR (1) CR20170482A (enExample)
DO (1) DOP2017000246A (enExample)
EA (1) EA035332B1 (enExample)
ES (1) ES2884267T3 (enExample)
HK (1) HK1243432A1 (enExample)
IL (1) IL255122A0 (enExample)
MA (2) MA56222A (enExample)
MX (1) MX2017013687A (enExample)
PE (1) PE20180162A1 (enExample)
PH (1) PH12017501914A1 (enExample)
PT (1) PT3286212T (enExample)
SG (1) SG11201708441RA (enExample)
TW (1) TW201643185A (enExample)
UY (1) UY36650A (enExample)
WO (1) WO2016171980A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106755100A (zh) * 2017-02-20 2017-05-31 李因传 可控性hiv‑1基因组靶向编辑系统和其靶向载运系统
US20240239877A1 (en) * 2017-12-18 2024-07-18 Viiv Healthcare Uk (No. 5) Limited Antigen binding polypeptides
CN108997482B (zh) * 2018-08-09 2025-09-09 东莞市朋志生物科技有限公司 用于检测hiv-1的合成肽
WO2021081515A2 (en) * 2019-10-25 2021-04-29 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus
CA3230492A1 (en) * 2021-08-30 2023-03-09 Kanglin Biotechnology (Hangzhou) Co., Ltd. Gene sequence construct for gene therapy for hiv infection

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US5672502A (en) 1985-06-28 1997-09-30 Celltech Therapeutics Limited Animal cell culture
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
JP3051145B2 (ja) 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ATE332368T1 (de) 1997-01-21 2006-07-15 Gen Hospital Corp Selektion von proteinen mittels rns-protein fusionen
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU2265701A (en) * 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
AU2001277867B2 (en) 2000-07-11 2006-12-07 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
AU2003299085B2 (en) * 2002-09-27 2008-04-10 Tanox, Inc. Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
CL2008002092A1 (es) 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
WO2009083804A2 (en) 2007-12-27 2009-07-09 Novartis Ag Improved fibronectin-based binding molecules and their use
EA201001734A1 (ru) 2008-05-02 2011-10-31 Новартис Аг Улучшенные связывающие молекулы на основе фибронектина и их применение
ES2705714T3 (es) 2008-10-31 2019-03-26 Janssen Biotech Inc Métodos y usos de dominio de Fibronectina tipo III basado en estructuras de composiciones
GB0920944D0 (en) * 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
WO2011077093A1 (en) * 2009-12-22 2011-06-30 Aarhus Universitet Bivalent molecules for hiv entry inhibition
EP2558491B1 (en) * 2010-04-13 2018-07-04 Bristol-Myers Squibb Company Fibronectin based scaffold domain proteins that bind pcsk9
TW201138808A (en) * 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
CN102939538A (zh) * 2010-05-07 2013-02-20 霍夫曼-拉罗奇有限公司 用于离体检测细胞的诊断方法
CN103380143B (zh) 2010-12-22 2016-01-06 百时美施贵宝公司 结合il-23的基于纤连蛋白的支架结构域蛋白质
WO2012159164A1 (en) 2011-05-23 2012-11-29 Phylogica Limited Method of determining, identifying or isolating cell-penetrating peptides
JP6440496B2 (ja) 2011-09-27 2018-12-19 ヤンセン バイオテツク，インコーポレーテツド 選択的結合表面を有するフィブロネクチンｉｉｉ型反復ベースのタンパク質スカフォールド
EP2951206A2 (en) * 2013-02-01 2015-12-09 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP2968587A2 (en) * 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
CN103333255A (zh) 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂

Similar Documents

Publication Publication Date Title
JP2018516247A5 (enExample)
JP7682150B2 (ja) プロテアーゼ活性化治療剤を含む組成物および方法
JP2016000731A5 (enExample)
JP2014530253A5 (enExample)
JP2024102211A5 (enExample)
JP2015509097A5 (enExample)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
JP2023506765A5 (enExample)
JP2019503990A5 (enExample)
JP2023504914A5 (enExample)
JP2018522563A5 (enExample)
JP2015522576A5 (enExample)
JP2019531093A5 (enExample)
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
JP2016052315A5 (enExample)
JP2017514522A5 (enExample)
JP2019524687A5 (enExample)
JP2012082206A5 (enExample)
NZ591130A (en) Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof
JP2013534812A5 (enExample)
FI3368555T3 (fi) Kaksitoimisia proteiineja ja niitä sisältävä farmaseuttinen koostumus
JP2017518303A5 (enExample)
JP2014526881A5 (enExample)
JP2009520758A5 (enExample)
JP2016504993A5 (enExample)